Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18135074 | 1.00 | BACE1 (0.42) | BACE1MMP2KMT2ACHRNB2CHRNB4 | |
| SCHEMBL18129434 | 1.00 | BACE1 (0.42) | BACE1MMP2KMT2ACHRNB2CHRNB4 | |
| Hydrochloric Acid SCHEMBL22468429 | 0.98 | BACE1 (0.41) | BACE1MMP2KMT2A | |
| Hydrochloric Acid SCHEMBL22468432 | 0.98 | BACE1 (0.41) | BACE1MMP2KMT2A | |
| SCHEMBL26572786 | 0.85 | BACE1 (0.32) | BACE1 | |
| SCHEMBL9733517 | 0.83 | MMP2 (0.35) | BACE1MMP2KMT2A | |
| SCHEMBL8291336 | 0.82 | GRM2 (0.32) | — | |
| SCHEMBL26114376 | 0.78 | CYP1A2 (0.48) | KMT2A | |
| SCHEMBL7380804 | 0.78 | CYP1A2 (0.48) | KMT2A | |
| SCHEMBL8577271 | 0.78 | CYP1A2 (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| WO-2014082380-A1 | FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| EP-2730572-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Sunshine Lake Pharma Co., Ltd (CN) | 2014-05-14 | — | — | EP | disclosed |
| EP-0574174-B1 | Angiotensin II antagonists | LILLY CO ELI (US) | 2003-08-13 | — | — | EP | disclosed |
| US-5693633-A | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5612360-A | AROMATIC N-HETEROCYCLIC COMPOUNDS AS HYPOTENSIVE AGENTS WITH ACID GROUPS, SULFONYLCARBOXAMIDES OR TETRAZOLE GROUPS | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5569768-A | USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5556981-A | Angiotensin II antagonist intermediates | ELI LILLY AND COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | BACE1 987/4885MMP2 3693/4885KMT2A 4590/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | BACE1 515/4885MMP2 3537/4885KMT2A 4601/4885 |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | BACE1 1780/4885MMP2 2918/4885KMT2A 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.